Key result
Managing CAD in elderly PCI patients requires age-tailored tools to balance ischemic and bleeding risks.
Why the study?
Balancing thrombotic and bleeding risks post-PCI is particularly challenging in elderly patients, and the applicability of bleeding risk stratification tools in this population remains uncertain.
This review highlights the complexities of managing elderly CAD patients undergoing PCI, emphasizing the need for improved, tailored risk assessment methods for bleeding and ischemic complications.
Emphasizes cautious antithrombotic choices in elderly PCI patients; leaves open prospective validation of age-specific risk tools.
The care of elderly patients with coronary artery disease (CAD) undergoing percutaneous coronary interventions (PCIs) presents unique challenges due to age-related physiological and functional changes. With the global population aging rapidly, this demographic change affects a growing proportion of individuals requiring PCI. However, advanced age is associated with increased susceptibility to ischemic and bleeding complications, driven by physiological changes such as altered coagulation, vascular stiffness, and declining organ function. These factors complicate the management of CAD, making the balance between reducing thrombotic events and minimizing bleeding risks particularly challenging. Antiplatelet therapy is central to post-PCI management, but its benefits and risks differ significantly in elderly patients compared to younger populations. Tools like the PRECISE-DAPT and ARC-HBR provide guidance on dual antiplatelet therapy duration and bleeding risk stratification. However, their applicability and predictive accuracy in elderly patients remain areas of active investigation. This underscores the need for improved risk assessment methods tailored to the unique needs of aging individuals. In this review, we explore the epidemiological, pathophysiological, and clinical aspects of CAD in elderly patients, emphasizing the impact of aging on disease presentation and outcomes. Furthermore, we assess current risk stratification tools and discuss their limitations in predicting adverse events in older populations. By synthesizing these insights, we aim to highlight the complexities of managing elderly CAD patients and identify opportunities for optimizing personalized care to achieve better outcomes in this vulnerable group.
No takes yet. Share an insight, caveat, or question.
Marschall et al. (2025) conducted a review in Coronary artery disease in elderly patients undergoing percutaneous coronary intervention. Antiplatelet therapy and risk stratification tools (PRECISE-DAPT, ARC-HBR) was evaluated. Managing coronary artery disease in elderly patients undergoing percutaneous coronary intervention requires balancing ischemic and bleeding risks, highlighting the need for age-tailored risk tools.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: